Drug Profile
Research programme: neurodegenerative disease therapeutics - AstraZeneca
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Link Medicine Corporation
- Developer AstraZeneca
- Class Small molecules
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neurodegenerative disorders